Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Interpace Diagnostics Group (IDXG)
OTHER OTC:IDXG
Holding IDXG?
Track your performance easily
IDXG Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.78 - $3.54
Previous Close$2.84
Volume5.50K
Average Volume (3M)11.78K
Market Cap
$11.72M
Enterprise Value$16.48M
Total Cash (Recent Filing)$2.11M
Total Debt (Recent Filing)$6.88M
Price to Earnings (P/E)2.7
Beta1.94
Next Earnings
Mar 26, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.07
Shares Outstanding4,404,795
10 Day Avg. Volume9,198
30 Day Avg. Volume11,783
Standard Deviation0.35
R-Squared0.01
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)-0.22
Price to Sales (P/S)0.28
Price to Cash Flow (P/CF)1.50
P/FCF Ratio1.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.38
Enterprise Value/Gross Profit0.69
Enterprise Value/Ebitda3.39
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Interpace Diagnostics Group News
PremiumCompany Announcements
Interpace Biosciences Reports Impressive Q3 2024 Growth
PremiumCompany Announcements
Interpace Diagnostics Strategic Stock Exchange for Nasdaq Uplisting
Ownership Overview
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
IDXG FAQ
What was Interpace Diagnostics Group’s price range in the past 12 months?
Interpace Diagnostics Group lowest stock price was $0.78 and its highest was $3.54 in the past 12 months.
What is Interpace Diagnostics Group’s market cap?
Currently, no data Available
When is Interpace Diagnostics Group’s upcoming earnings report date?
Interpace Diagnostics Group’s upcoming earnings report date is Mar 26, 2025 which is in 94 days.
How were Interpace Diagnostics Group’s earnings last quarter?
Interpace Diagnostics Group released its earnings results on Nov 04, 2024. The company reported $0.289 earnings per share for the quarter, beating the consensus estimate of N/A by $0.289.
Is Interpace Diagnostics Group overvalued?
According to Wall Street analysts Interpace Diagnostics Group’s price is currently Overvalued.
Does Interpace Diagnostics Group pay dividends?
Interpace Diagnostics Group does not currently pay dividends.
What is Interpace Diagnostics Group’s EPS estimate?
Interpace Diagnostics Group’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Interpace Diagnostics Group have?
Interpace Diagnostics Group has 4,404,795 shares outstanding.
What happened to Interpace Diagnostics Group’s price movement after its last earnings report?
Interpace Diagnostics Group reported an EPS of $0.289 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 22.541%.
Which hedge fund is a major shareholder of Interpace Diagnostics Group?
Currently, no hedge funds are holding shares in IDXG
---
Interpace Diagnostics Group Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
184.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.48%
Trailing 12-Months
Company Description
Interpace Diagnostics Group
Interpace Biosciences, Inc. operates as an bioinformatics company, which engages in the development and commercialization of molecular diagnostic test and pathology services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment; ThyGenX and PathFinderTG which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. The company was founded by John P. Dugan in 1987 and is headquartered in Parsippany, NJ.
---
Technical Analysis
---